Binding Site


Clinical laboratory diagnostics

Binding Site is a specialised diagnostics company producing protein tests for diagnosis of certain blood cancer diseases as well as immunological disorders. With extensive expertise in antibody specificity technology, Binding Site gives clinicians and laboratory staff the tools to significantly improve diagnosis and management of patients across a range of cancers and immune system disorders.

The UK head office houses all product development, manufacturing, global distribution and marketing. Worldwide customer support is also provided by a further 7 offices in the US and Europe.

Binding Site was acquired by Nordic Capital Fund VII in 2011.

  • Charles de Rohan, CEO
  • Mark Culwick, CFO
Key Information: Revenues 2016*: EUR 120 million Employees: 730 Ownership: Nordic Capital Fund VII, controlling shareholding Date of investment: 2011 Head office: Birmingham, UK
* Reported